C4 Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
C4 Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • C4 Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$28.2M, a 1.57% decline year-over-year.
  • C4 Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$119M, a 14.7% increase year-over-year.
  • C4 Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$139M, a 7.33% decline from 2022.
  • C4 Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$130M, a 57.7% decline from 2021.
  • C4 Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$82.1M, a 35.9% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$139M -$9.5M -7.33% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$130M -$47.4M -57.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$82.1M -$21.7M -35.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-23
2020 -$60.4M -$25M -70.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-24
2019 -$35.5M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.